Table 3 Summary of randomized trials of mild hypofractionated radiotherapy
Study | MDACC (33) | FCCC (34, 35) | RENCI (31, 36, 37) | UK CHHiP (32) | Current study |
|---|---|---|---|---|---|
Dose/fractions (EQD2 α/β = 1.4) | 72 Gy/30 (80Gy) vs 75.6 Gy/ 42 (71 Gy) | 70.2 Gy/26 (84 Gy) vs 76 Gy/38 | 62 Gy/20 (82 Gy) vs 80 Gy/40 | 60 Gy/20 (77.6 Gy); 57 Gy/19 (73.8 Gy) vs 74 Gy/37 | 42 Gy/21 plus 30 Gy/10 (81 Gy) |
Median F/U (yrs) | 4.8 | 5 | 2.9 | 4.2 | 7.2 |
*PTV margins (mm) | Not reported | Ant/Sup/Inf/RL7 Post 3 | 10 | PTV1 (80%) | Phase 1 - 10 |
 Ant/Sup/Inf/RL 10 | Phase 2 | ||||
 Post 10 |  AP 4 | ||||
PTV2 (96%) |  SI 3 | ||||
 Ant/Sup/Inf/RL 10 |  RL 3 | ||||
 Post 5 |  | ||||
PTV3 (100%) | Â | ||||
 Ant/Sup/Inf/RL 5 |  | ||||
 Post 0 |  | ||||
*LateToxicity (%) | RTOG | NR | RTOG | RTOG | RTOG |
≥ Grade 2 | |||||
GI | 11 | 6 | 17 | 3.6 (60 Gy); 1.4 (57 Gy) | 21 |
GU | 19 | 14 | 14 | 2.2 (60 Gy); 0 (57 Gy) | 3 |
Grade 3 | |||||
GI | 3 | NR | 1 patient | none | none |
GU | 0 | NR | none | none | none |
Grade 4 | |||||
GI | none | NR | none | none | none |
GU | none | NR | none | none | none |
Biochemical control (%) | Phoenix | Phoenix | Phoenix | Â | Phoenix |
5Â yr - 97 vs 94 | 5Â yr - 86 vs 86 | 5Â yr - 85 vs 79 | NR | 5Â yr - 87 | |
ASTRO |  |  |  | 7 yr – 77 | |
5Â yr - 96 vs 92 | Â | Â | Â | 9Â yr - 66 | |